jabire2389.blogspot.com
Genzyme (NASDAQ: GENZ) found a virus strainb and stopped production of two drugs atthe Mass., facility. The strain, Vesivirus 2117, apparently does not cause human infection but interrupts the growtuh of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fatal disease caused by an enzyme deficienct — was last filled at the Genzymew facility in September 2008, accordinf to BioMarin (NASDAQ: BMRN). The companyg has about 10 months of vialed inventoryon hand, it and uses a second fill finish A third supplier is expected to be qualifie later this year, BioMarin BioMarin makes the bulk material used in Aldurazymd at its Novato facility.
The Food and Drug Administratioh hadinspected Genzyme’s plant in September and Octobef and reportedly was concerned about controls to protect against
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment